	US 12,472,183 B2
	Anti-ischemic compositions
Bengt Fagrell, Taby (SE); Jeffrey G. Parker, Palm Springs, CA (US); and Nils U. Olsson, San Diego, CA (US)
Assigned to Bengt Fagrell, Taby (SE); Jeffrey G. Parker, Wrightwood, CA (US); and Nills U. Olsson, San Diego, CA (US)
Appl. No. 17/633,147
Filed by Seraphim Therapeutics, Inc., Evansville, IN (US)
PCT Filed Aug. 4, 2020, PCT No. PCT/US2020/044905 § 371(c)(1), (2) Date Feb. 4, 2022, PCT Pub. No. WO2021/026169, PCT Pub. Date Feb. 11, 2021.
Claims priority of provisional application 62/882,912, filed on Aug. 5, 2019.
Prior Publication US 2022/0354850 A1, Nov. 10, 2022
Int. Cl. A61K 38/05 (2006.01); A61K 9/16 (2006.01); A61K 31/519 (2006.01); A61K 38/01 (2006.01); A61K 38/42 (2006.01); A61P 7/08 (2006.01); A61P 9/10 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/16 (2013.01); A61K 38/012 (2013.01)]

13 Claims

1. A composition, comprising:

a purified erythrocruorin; and

5-methyltetrahydrofolate, 5-formyltetrahydrofolate, or 5-methyltetrahydrofolate and 5-formyltetrahydrofolate,

wherein the composition optionally comprises 5,6,7,8-tetrahydrobiopterin.